Solti-1303 Patricia 2 Randomized Phase Ii Trial Of Palbociclib Plus Trastuzumab And Endocrine Therapy (Et) Versus Treatment Of Physician'S Choice (Tpc) In Metastatic Her2-Positive And Hormone Receptor-Positive (Her2+/Hr+) Breast Cancer (Bc) With Pam50 Luminal Intrinsic Subtype

ANNALS OF ONCOLOGY(2021)

引用 3|浏览4
暂无评分
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要